Table 3 Allopurinol use
From: Chronic kidney disease in gout in a managed care setting
Patient characteristics | No CKD (N = 2,393) | Stage 2 CKD (N = 1,032) | Stage 3 CKD (N = 357) | Stage 4 CKD (N = 147) | p-value | |
|---|---|---|---|---|---|---|
Used allopurinol during follow-up period, including index date | N | 1,855 | 826 | 312 | 129 | |
% | 77.52 | 80.04 | 87.39 | 87.76 | < .0001 | |
Initial daily dose (mg) | N | 1,855 | 826 | 312 | 129 | |
Mean | 248.17 | 249.02 | 233.78 | 217.63 | 0.0023 | |
Std | 107.41 | 107.45 | 103.73 | 104.55 | ||
Median | 300 | 300 | 300 | 200 | ||
Last daily dose (mg) | N | 1,552 | 699 | 260 | 109 | |
Mean | 268.93 | 261.63 | 248.08 | 241.54 | 0.0021 | |
Std | 106.46 | 102.43 | 94.11 | 127.4 | ||
Median | 300 | 300 | 300 | 300 | ||
Difference between last dose and initial dose among subjects who titrated (mg) | N | 269 | 108 | 53 | 36 | |
Mean | 106.02 | 102.73 | 66.26 | 86.33 | 0.5366 | |
std | 192.07 | 188.55 | 167.93 | 187.99 | ||
Subjects who titrated | n | 270 | 108 | 53 | 36 | |
% | 14.56 | 13.08 | 16.99 | 27.91 | 0.00014 | |
Increased between first and last dose | n | 213 | 87 | 37 | 27 | |
% | 78.89 | 80.56 | 69.81 | 75 | 0.4253 | |
Decreased between first and last dose | n | 57 | 21 | 16 | 9 | |
% | 21.11 | 19.44 | 30.19 | 25 | 0.4253 |